Skip to main content
. 2005 May 12;33(2):145–152. doi: 10.1165/rcmb.2004-0330OC

Figure 1.

Figure 1.

(a) Infusion of BMDMSC prevented mortality in mice myelosuppressed with busulfan before bleomycin. Sixty-six percent of myelosuppressed mice (n = 6) given bleomycin died without BMDMSC transfer. There was no mortality in any of the other experimental groups (n = 5 animals per group). Histologic sections of lungs obtained from: (b, c) normal C57BL/6 mice; (d, e) 14 d after 4 U/kg busulfan (lungs appear normal); (f, g) 14 d after bleomycin (increased cellularity and fibrosis typical of bleomycin injury); (h, i) 14 d after bleomycin following busulfan myelosuppression (apparently more extensive increased cellularity and fibrosis compared with f and g); (j, k) 14 d after bleomycin followed by BMDMSC transfer (minimal alterations in lung architecture compared with f and g); (l, m) 14 d after bleomycin followed by BMDMSC transfer in myelosuppressed mice showing apparent protection (compare with h and i), but more abnormalities than present in the BMDMSC transplanted mice without myelosuppression (compare with j and k).